Skip to search formSkip to main contentSkip to account menu

Biological Response Modifiers Program

Known as: BRMP 
A program set up to establish cooperative agreements for Clinical Trials of Cancer Therapy with Biological Response Modifiers (CATBRMs) and to… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Switching between standard coral reef benthic monitoring protocols is complicated: proof of concept
Monitoring the state of coral reefs is necessary to identify drivers of change and assess effectiveness of management actions… 
Review
2015
Review
2015
A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit–Risk Assessment of Medicines
The comparative evaluation of benefits and risks is one of the most important tasks during the development, market authorization… 
2011
2011
The benefits quantification method: a practical approach to engaging stakeholders in the judgement of benefits realisation
The Benefits Quantification Method (BQM) is a practical approach to engaging stakeholders in the definition and judgement of… 
Review
2010
Review
2010
Quantifying the benefits of healthcare infrastructure investment
UK government seeks the use of Benefits Realisation Management Processes (BRMPs) to direct capital investments that are… 
Review
2002
Review
2002
Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase.
Benzamide riboside (BR) is a nucleoside prodrug that is phosphorylated to its 5'-monophosphate (BRMP) and then converted to its… 
2002
2002
Environment monitoring and assessment in GNPS
Two PWR units at Guangdong Daya Bay Nuclear Power Station (GNPS) in China have been putting into commercial operation in… 
1998
1998
Adenovirus‐Mediated Interleukin‐2 Production by Tumors Induces Growth of Cytotoxic Tumor‐Infiltrating Lymphocytes Against Human Renal Cell Carcinoma
Combination therapy with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes (TILs) demonstrates significant clinical… 
1990
1990
Phase I trial with recombinant interleukin‐2 (rIL‐2): immune activation by rIL‐2 alone or following pretreatment with recombinant interferon‐gamma
Alterations of imniunological parameters were analysed in patients with advanced malignancies during a phase I trial with rIL‐2… 
1986
1986
The BRMP IL-2 reference reagent.
The BRMP has established an interim IL 2 Reference Reagent. Unitage was assigned after a collaborative, 7 laboratory study. The… 
1982
1982
Biological Response Modifiers Programme and cancer chemotherapy.
The Biological Response Modifiers Programme (BRMP) is a comprehensive programme of the National Cancer Institute to evaluate the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)